Provided by Tiger Fintech (Singapore) Pte. Ltd.

Prelude Therapeutics Inc

0.7120
-0.0240-3.26%
Volume:44.84K
Turnover:32.18K
Market Cap:39.19M
PE:-0.40
High:0.7640
Open:0.7200
Low:0.7120
Close:0.7360
Loading ...

Optimism in Prelude Therapeutics: Buy Rating Backed by Promising PRT3789 Trial Results

TIPRANKS
·
28 Oct 2024

Prelude Therapeutics price target lowered to $1 from $3 at Barclays

TIPRANKS
·
27 Oct 2024

Prelude Therapeutics: Sell Rating Due to Limited Efficacy Improvement and Financial Challenges

TIPRANKS
·
26 Oct 2024

Buy Rating Affirmed for Prelude Therapeutics Amid Positive Developments in PRT3789 and Strong Financial Position

TIPRANKS
·
25 Oct 2024

Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium

GlobeNewswire
·
24 Oct 2024

Prelude announces publication of abstracts on SMARCA Degrader Programs

TIPRANKS
·
09 Oct 2024

Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium

GlobeNewswire
·
09 Oct 2024

Prelude Therapeutics Raised to Buy From Neutral by HC Wainwright & Co.

Dow Jones
·
19 Sep 2024

Prelude Therapeutics Inc : H.c. Wainwright Raises to Buy From Neutral

THOMSON REUTERS
·
19 Sep 2024

HC Wainwright Upgrades Prelude Therapeutics to Buy From Neutral

MT Newswires Live
·
19 Sep 2024

We're Keeping An Eye On Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Rate

Simply Wall St.
·
16 Sep 2024

Prelude Therapeutics Price Target Maintained With a $5.00/Share by HC Wainwright & Co.

Dow Jones
·
16 Sep 2024

Hold Rating on Prelude Therapeutics Amid Cautious Optimism for PRT3789’s Early Promise

TIPRANKS
·
16 Sep 2024

Prelude Therapeutics (PRLD) Gets a Sell from Barclays

TIPRANKS
·
16 Sep 2024

Buy Rating Affirmed for Prelude Therapeutics on Promising PRT3789 Trial Results and Strong Financial Position

TIPRANKS
·
16 Sep 2024

Prelude Therapeutics: Uncertainties in Drug Efficacy and Dosing Prompt Sell Rating

TIPRANKS
·
14 Sep 2024